ONCY ONCOLYTICS BIOTECH INC
Price Chart
Executive Summary
Oncologics Biotech announced initial preclinical data showing pelareorep combined with RAS inhibitors demonstrates greater anti-tumor activity in solid tumor models. The company plans additional studies in pancreatic and colorectal cancer, with full data expected in late 2026. This early-stage preclinical news provides a minor catalyst but no financial impact.
Actionable Insight
Monitor for full preclinical data presentation in late 2026, which could serve as a catalyst if results are compelling. Near-term stock movement likely muted given early stage.
Key Facts
- Pelareorep + RAS inhibitor modalities showed greater anti-tumor activity than individual approaches in a solid tumor model
- Additional studies planned in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) models
- Full results from initial preclinical studies expected in fall or winter 2026
- No financial terms or material agreements disclosed
Financial Impact
No financial figures provided; preclinical stage, no immediate revenue or expense impact
Risk Factors
- Preclinical results may not translate to clinical efficacy
- No financial data or guidance provided
- Small-cap biotech volatility with low liquidity
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000037 |
| Document: 0001129928-26-000037-index-headers.html | 0001129928-26-000037 |
| Document: 0001129928-26-000037-index.html | 0001129928-26-000037 |
| Document: 0001129928-26-000037.txt | 0001129928-26-000037 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
12d ago
|
8-K
| $0.9300 $0.8800 | ▼ −5.38% | ▼ −4.68% | $0.8000 (−13.98%) |
|
Jun 1, 2026
13d ago
|
8-K
| $1.06 $0.9300 | ▼ −12.26% | ▼ −12.41% | $0.8000 (−24.53%) |
|
May 22, 2026
23d ago
|
8-K
| $0.8100 $0.8100 | · 0.00% | ▼ −0.59% | $0.8000 (−1.23%) |
|
May 22, 2026
23d ago
|
Press Release
| $0.8100 $0.8100 | · 0.00% | ▼ −0.59% | $0.8000 (−1.23%) |
|
Apr 27, 2026
6w ago
|
8-K
| $0.9700 $0.9000 | ▼ −7.22% | ▼ −6.73% | $0.8000 (−17.53%) |
|
Apr 6, 2026
9w ago
|
424B5
| $0.9000 $0.9100 | ▼ −1.11% | ▲ +1.43% | $0.8000 (+11.11%) |
|
Apr 6, 2026
9w ago
|
8-K
| $0.9500 $0.9000 | ▼ −5.26% | ▼ −5.33% | $0.8000 (−15.79%) |
|
Apr 6, 2026
10w ago
|
EFFECT
| $0.9500 $0.9000 | ▲ +5.26% | ▲ +5.33% | $0.8000 (+15.79%) |
|
Apr 1, 2026
10w ago
|
S-3
| $0.9300 $0.9600 | ▼ −3.23% | ▼ −3.15% | $0.8000 (+13.98%) |
|
Mar 11, 2026
13w ago
|
Insider Cluster
| $1.01 $0.9600 | ▼ −4.95% | ▼ −3.47% | $0.8000 (−20.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access